A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE

被引：10

作者：

Powles, Thomas

Galsky, Matt D.

Castellano, Daniel

Van Der Heijden, Michiel Simon

Petrylak, Daniel Peter

Armstrong, Jon

Belli, Riccardo

Ferro, Salvatore

Ben, Yong

Bellmunt, Joaquim

机构：

[1] Queen Mary Univ London, Barts Canc Inst, London, England

[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[3] Hosp Univ 12 Octubre, Madrid, Spain

[4] Netherlands Canc Inst, Amsterdam, Netherlands

[5] Yale Univ, New Haven, CT USA

[6] AstraZeneca, Alderley Pk, England

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, Gaithersburg, MD USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS4574

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4574

引用

页数：2